Bristol-myers Squibb Stock News

The "Halftime Report" traders give their top picks to watch for the second half.

Financial Counselors Inc. decreased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.9% during the third quarter, HoldingsChannel reports. The institutional investor owned 170,268 shares of the biopharmaceutical company’s stock after selling 3,378 shares during the period. Financial Counselors Inc.’s holdings in Bristol-Myers Squibb were worth $10,075,000 at the end of the most recent […]

The pharma has expanded an alliance with a German biotech by paying $150 million for a drug candidate that executives hope can have "cell therapy-like efficacy" for solid tumors.

TUEBINGEN, Germany & HOUSTON & NEW YORK--(BUSINESS WIRE)---- $BMY--Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics TCR Bispecific Program IMA401

Los Angeles, USA, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Glioblastoma Pipeline Analysis | Clinical Trials Report 2021 | DelveInsight There are approximately 150+ key companies developing Glioblastoma therapies. The companies with Glioblastoma drug candidates in the most advanced stage are Kintara Therapeutics, Diffusion Pharmaceuticals, Celgene Corporation, Bio-Thera Solutions. DelveInsight''s " Glioblastoma Pipeline Insight " report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Glioblastoma pipeline landscapes. It comprises Glioblastoma pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Glioblastoma therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Glioblastoma pipeline products. Some of the key takeaways from the Glioblastoma Pipeline Report Major companies such as Celgene Corporation, Myeloid Therapeutics, Genenta Science, Inovio Pharmaceuticals, Apogenix, Oncoceutics, Laminar Pharmaceuticals, Celgene Corporation, Bristol-Myers Squibb, Kintara Therapeutics, Kazia Therapeutics, Oncotelic Therapeutics, AstraZeneca, Genentech, Accendatech, Pfizer, Curtana Pharmaceuticals, Crimson BioPharm, Hope Biosciences, and others are developing potential drug candidates to improve the Glioblastoma treatment scenario.

In acquiring Arena, Pfizer aims to compete head-to-head with Bristol-Myers Squibb’s Zeposia® (ozanimod), first approved in 2020 for relapsing forms of multiple sclerosis. On May 27, Zeposia won FDA approval as the first and to-date only S1P receptor modulator approved for treating moderately to severely active UC. Zeposia generated $40 million in product revenue during the third quarter, up from $2 million in Q3 2020. The post Pfizer to Acquire Arena for $6.7B, Expanding Immuno-Inflammatory Pipeline appeared first on GEN - Genetic Engineering and Biotechnology News .

A revamped shareholder rewards program has investors piling into this beaten-down pharma stock today.

A revamped shareholder rewards program has investors piling into this beaten-down pharma stock today.

Check out these pharmaceutical players on the move now.

Bristol-Myers Squibb Co (NYSE: BMY) is trading higher Monday after the company announced an additional $15 billion buyback and raised its quarterly dividend. Bristol-Myers authorized the repurchase o

NEW YORK--(BUSINESS WIRE)---- $BMY--Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization

Bristol Myers Squibb & Co (NYSE: BMY ) released the first disclosure of results from a prespecified interim analysis of Phase 3 TRANSFORM study of Breyanzi (lisocabtagene maraleucel; liso-cel). Breyanzi cut the risk of disease progression, death, and other events by 65% over the standard of care in patients with second-line relapsed or refractory large B-cell lymphoma (LBCL). These data back up results toplined in June , Full story available on Benzinga.com

New Jersey, United States,- Verified Market Research has recently published a research report titled, Rheumatoid Arthritis Therapeutics Market Size, and Forecast 2021-2028, Breakdown Data by Manufacturers, Key Regions, Types and Application. Primary and secondary research methodologies have been used to

Bristol Myers Squibb Co. shares BMY, -2.05% rose 2% in premarket trade Monday, after the company announced a 10.2% increase in its quarterly dividend and added $15 billion to its share buyback authori

The Angioimmunoblastic T-Cell Lymphoma Market report aims to convey an inexpensive understanding of the business which has been analyzed by using primary and secondary research strategies. the main purpose of this Angioimmunoblastic T-Cell Lymphoma Market report is to supply an